# Yves Pommier

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yves-pommier/

## Facts

| Field | Value |
| --- | --- |
| Citations | 81,252 |
| Field | Cancer therapeutics and mechanisms |
| h-index | 139 |
| i10-index | 788 |
| Last Known Institution | Office of the Director |
| OpenAlex ID | https://openalex.org/A5042114293 |
| ORCID iD | 0000-0002-3108-0758 |
| Works | 2,071 |

## Researcher papers

Showing 12 of 14.

- [Topoisomerase I inhibitors: camptothecins and beyond](https://scholariq.org/papers/topoisomerase-i-inhibitors-camptothecins-and-beyond/)
- [Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors](https://scholariq.org/papers/trapping-of-parp1-and-parp2-by-clinical-parp-inhibitors/)
- [DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs](https://scholariq.org/papers/dna-topoisomerases-and-their-poisoning-by-anticancer-and-antibacterial-drugs/)
- [γH2AX and cancer](https://scholariq.org/papers/h2ax-and-cancer/)
- [A gene expression database for the molecular pharmacology of cancer](https://scholariq.org/papers/a-gene-expression-database-for-the-molecular-pharmacology-of-cancer/)
- [Roles of eukaryotic topoisomerases in transcription, replication and genomic stability](https://scholariq.org/papers/roles-of-eukaryotic-topoisomerases-in-transcription-replication-and-genomic/)
- [CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set](https://scholariq.org/papers/cellminer-a-web-based-suite-of-genomic-and-pharmacologic-tools-to-explore/)
- [Drugging Topoisomerases: Lessons and Challenges](https://scholariq.org/papers/drugging-topoisomerases-lessons-and-challenges/)
- [Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action](https://scholariq.org/papers/laying-a-trap-to-kill-cancer-cells-parp-inhibitors-and-their-mechanisms-of/)
- [Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib](https://scholariq.org/papers/stereospecific-parp-trapping-by-bmn-673-and-comparison-with-olaparib-and/)
- [MGMT Status as a Clinical Biomarker in Glioblastoma](https://scholariq.org/papers/mgmt-status-as-a-clinical-biomarker-in-glioblastoma/)
- [Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study](https://scholariq.org/papers/durvalumab-in-combination-with-olaparib-in-patients-with-relapsed-sclc-results/)

## Researcher topics

- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)
- [DNA Repair Mechanisms](https://scholariq.org/topics/dna-repair-mechanisms/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [HIV/AIDS drug development and treatment](https://scholariq.org/topics/hiv-aids-drug-development-and-treatment/)

## Researcher university

- [Office of the Director](https://scholariq.org/institutions/office-of-the-director/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.